Abstract: The present invention relates to compounds of formula (I): for use as peripheral NMDA receptor antagonists.

Abstract: The present invention relates to compounds of formula (I); for use as peripheral NMDA receptor antagonists.

Abstract: The present invention relates to compounds of formula (I): for use as peripheral NMDA receptor antagonists.

Abstract: The present invention relates to compounds of formula (I) for use as peripheral NMDA receptor antagonists.

Abstract: The present invention relates to the fields of medicine and in particular cancer treatment. The invention more specifically relates to new compounds which are typically for use as a medicament. In particular, the invention relates to the use of these new compounds for increasing the presentation, typically the production and presentation, of Pioneer Translation Products (PTPs)-derived antigens by cells, in particular cancer cells, or changing the immunopeptidome, in a subject, and inducing or stimulating an immune response in the subject. The present disclosure also relates to uses of such compounds, in particular to prepare a pharmaceutical composition and/or to allow or improve the efficiency of a therapy in a subject in need thereof. The invention also discloses methods for treating a disease, in particular cancer, for preventing or treating cancer metastasis and/or cancer recurrence, in a subject.

Abstract: The present invention relates to the field of prevention and treatment of diseases involving NMDA receptors of the central nervous system. It relates more specifically to compounds of 1-(indol-3-yl)-3-hydroxy-3-(2-oxo-2-ethyl)-indol-2-ones type, as a drug, and the use of such compounds in the preparation of pharmaceutical compositions. These pharmaceutical compositions may in particular be intended to prevent or treat diseases involving NMDA receptors of the central nervous system, in particular severe/resistant epilepsy and cognitive disorders resulting therefrom, especially autism, but also strokes, schizophrenia, degenerative diseases involving the activation of NMDA receptors, such as Parkinson's disease and Alzheimer's disease, Rett syndrome, or amyotrophic lateral sclerosis, migraine, dementia and major depressive disorder.

Abstract: The present invention relates to the field of prevention and treatment of diseases involving NMDA receptors of the central nervous system. It relates more specifically to compounds of indole-1-yl-(1H)-quinoline-2-one and indole-3-yl-(1H)-quinoline-2-one type, as a drug, and the use of such compounds in the preparation of pharmaceutical compositions. These pharmaceutical compositions may in particular be intended to prevent or treat diseases involving NMDA receptors of the central nervous system, in particular severe/resistant epilepsy and cognitive disorders resulting therefrom, especially autism, but also strokes, schizophrenia, degenerative diseases involving the activation of NMDA receptors, such as Parkinson's disease and Alzheimer's disease, Rett syndrome, or amyotrophic lateral sclerosis, migraine, dementia and major depressive disorder.

Abstract: The present invention relates to the compounds of formula (I) below: wherein: X represents an oxygen atom, a sulfur atom, a nitrogen atom or a CH radical, The bond X—Y and Y are absent if X represents an oxygen or sulfur atom, the bond X—Y and Y are present if X represents a nitrogen atom or a CH radical, When present, Y represents a group R if X represents a nitrogen atom, a hydrogen atom or a group —NR1R2 if X represents a CH radical, (Het)Ar is an aromatic ring selected from the group consisting of aryl and heteroaryl groups, R3, R4, R5, R6 represent, independently of one another, a hydrogen atom, a halogen atom, a —NR12R13, a —SR14 group, a —OR14 group or a —CF3 group, When Y is —NR1R2, the groups —NR1R2 and (Het)Ar are in the cis-conformation, or a pharmaceutically acceptable salt thereof, for use in the treatment of proliferative diseases, infectious diseases, allergies, inflammation and/or asthma.

Abstract: The invention relates to compounds which are inhibitors of the polymerization of tubulin, to the methods for the production thereof, and to the uses of same.

Abstract: The present invention relates to cationic compounds of formula (I) for use as peripheral NMDA receptor antagonists.

Abstract: The present invention relates to compounds of formula (I) for use as peripheral NMDA receptor antagonists.

Abstract: The present invention relates to cationic compounds of formula (I) for use as peripheral NMDA receptor antagonists.

Abstract: The invention relates to compounds which are inhibitors of the polymerization of tubulin, to the methods for the production thereof, and to the uses of same.

Abstract: The invention relates to a compound of the formula (I) in which: R1, R2 and R3 are independently a methoxy group optionally substituted by one or more fluorine atoms; R4 is a hydrogen atom; R5 and R6 are identical and each represent a hydrogen or fluorine atom; A is a cycle selected from the group including aryl and heteroaryl groups, wherein said groups can be substituted.

Abstract: The present invention relates to compounds of formula (I) below in which: —R1 and R3 represent, independently of one another, a methoxy group optionally substituted by one or more fluorine atoms, —R2 and R4 represent, independently of one another, a hydrogen atom or a methoxy group optionally substituted by one or more fluorine atoms, —A represents a ring chosen from the group comprising aryl and heteroaryl groups, said ring possibly being substituted by or fused to a heterocycle, —X represents a nitrogen atom or a CH group, and —Z1 represents a hydrogen atom or a halogen atom, preferably fluorine, and —Z2 represents a hydrogen atom, a halogen atom, preferably fluorine, a C1 to C4 alkyl group, an aryl group or a —CN, —SO2NR12R13, —SO2R9, —COOR15 or —COR15 group, and also to the pharmaceutically acceptable salts thereof, the isomers thereof and the prodrugs thereof.

Abstract: The invention relates to a compound of the formula (I) in which: R1, R2 and R3 are independently a methoxy group optionally substituted by one or more fluorine atoms; R4 is a hydrogen atom; R5 and R6 are identical and each represent a hydrogen or fluorine atom; A is a cycle selected from the group including aryl and heteroaryl groups, wherein said groups can be substituted.